Browse Tag

Biocartis

Biocartis Announces Market Release of SeptiCyte® RAPID test on Idylla™

October 6, 2020October 6, 2020

Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the market release

Pharmaceutical News

Biocartis Receives EUR 1.2 million Grant for Development of Highly Innovative Idylla™ GeneFusion Assay

October 1, 2020October 1, 2020

Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has

Go toTop